Anamorelin HCl (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Anamorelin HCl (ANAM) is a novel, orally active, ghrelin receptor agonist in clinical development for the treatment of cancer cachexia. We report in vitro and in vivo studies evaluating the preclinical pharmacologic profile of ANAM. Methods: Fluorescent imaging plate reader and binding assays in HEK293 and baby hamster kidney cells determined the agonist and antagonist activity of ANAM, and its affinity for the ghrelin receptor. Rat pituitary cells were incubated with ANAM to evaluate its effect on growth hormone (GH) release. In vivo, rats were treated with ANAM 3, 10, or 30 mg/kg, or control orally, once daily for 6 days to evaluate the effect on food intake (FI) and body weight (BW), and once to assess GH response. In pigs, single (3.5 mg/kg) or continuous (1 mg/kg/day) ANAM doses were administered to assess GH and insulin‐like growth factor (IGF‐1) response. Results: ANAM showed significant agonist and binding activity on the ghrelin receptor, and stimulated GH release in vitro. In rats, ANAM significantly and dose‐dependently increased FI and BW at all dose levels compared with control, and significantly increased GH levels at 10 or 30 mg/kg doses. Increases in GH and IGF‐1 levels were observed following ANAM administration in pigs. Conclusion: ANAM is a potent and highly specific ghrelin receptor agonist with significant appetite‐enhancing activity, leading to increases in FI and BW, and a stimulatory effect on GH secretion. These results support the continued investigation of ANAM as a potential treatment of cancer anorexia‐cachexia syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479
Dodson, S., Baracos, V. E., Jatoi, A., Evans, W. J., Cella, D., Dalton, J. T., & Steiner, M. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061509-131248 · Cited by 319 · cited 1×
“The pathogenesis of CACS is complex and not completely understood, but altered metabolism, and reduced food intake contribute to loss of muscle mass and decrease in body weight [7–9].”
BackgroundNass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-9-200811040-00003 · Cited by 255
Garcia, J. M., & Polvino, W. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-594 · Cited by 129
Garcia, J. M., & Polvino, W. J. (2009) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.12.003 · Cited by 89 · cited 3×
“One of these studies also demonstrated that repeated administration of ANAM led to a decrease in GH response and increase in IGF1 levels when the Day 1 and corresponding Day 5/6 parameters were compared [25].”
BackgroundResult
Cited by
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Self-citationGarcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218
Self-citationAnorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia
Morley, J. E. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12192 · Cited by 149
Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
Bai, Y., Hu, Y., Zhao, Y., Yu, X., Xu, J., Hua, Z., & Zhao, Z. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3560-0 · Cited by 52
Nishie, K., Yamamoto, S., Nagata, C., Koizumi, T., & Hanaoka, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.023 · Cited by 52
Metadata
- Authors
- Pietra, C., Takeda, Y., Tazawa-Ogata, N., Minami, M., Yuanfeng, X., Duus, E. M., & Northrup, R.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2014-09-30
- Volume
- 5
- Issue
- 4
- Pages
- 329-337
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2010488274
- Cited by
- 114
- References
- 5
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anamorelin HCl (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile. https://app.cochat.ai/papers/10.1007/s13539-014-0159-5
- The paper
- Pietra, C., Takeda, Y., Tazawa-Ogata, N., Minami, M., Yuanfeng, X., Duus, E. M., & Northrup, R. (2014). Anamorelin HCl (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1007/s13539-014-0159-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.